GlaxoSmithKline is counting on new products like Breo Ellipta and Anoro Ellipta to extend its legacy in respiratory disease beyond Advair Diskus, which could face generic competition within the next five years. But GSK may need to wage a battle on the reimbursement front before it can claim commercial success – a challenge highlighted by Express Scripts’ unexpected decision to put Advair and Breo on its not covered list for 2014.
GlaxoSmithKline PLC’s launch of the first once-daily inhaled corticosteroid/long-acting beta2-agonist Breo Ellipta (fluticasone furoate/vilanterol) for chronic obstructive pulmonary disease (COPD) is a pivotal moment for the company.
Heavily dependent on its respiratory franchise, GSK needs Breo and new drugs like it to succeed if it is to...